The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy

Background The reimbursement for expensive medicines poses a growing challenge to healthcare worldwide. In order to increase its control over the costs of medicines, the Dutch government introduced the Coverage Lock (CL) policy in 2015. The CL postpones decisions regarding reimbursement of expensive...

Full description

Saved in:
Bibliographic Details
Published in:BMC health services research 2022-11, Vol.22 (1), p.1-9, Article 1320
Main Authors: Scheijmans, Féline E. V., Zomers, Margot L., Fadaei, Sina, Onrust, Marthe R., van der Graaf, Rieke, Delden, Johannes J. M. van, van der Pol, W. Ludo, van Thiel, Ghislaine J. M. W.
Format: Article
Language:English
Subjects:
Data analysis
Data collection
Drug therapy
Evaluation
Expensive medicines
Families & family life
Health Administration
Health care policy
Health Informatics
Health insurance
Health services
Healthcare policy
Interviews
Laws, regulations and rules
Medical care, Cost of
Medicine
Medicine & Public Health
Neuromuscular diseases
Nursing Research
Parents & parenting
Patient-centered care
Patients
Prescription drug plans
Public Health
Rare disease
Rare diseases
Reimbursement
Reimbursement policy
Spinal muscular atrophy
Stakeholders
The Netherlands
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!